Arcus Biosciences, Inc. — Institutional Ownership
Which tracked institutions hold RCUS, and how they changed the position last quarter. Latest holdings as of Mar 31, 2026. Source: SEC 13-F filings.
24
Funds holding
$1249546286
Total value held
Buying
17 added/new · 6 reduced
| # | Institution | Value | Shares | Δ Shares | Change (QoQ) |
|---|---|---|---|---|---|
| 1 | Gilead Sciences, Inc. | $678774816 | 31424760 | — | Held |
| 2 | Blackrock, Inc. | $328891861 | 15226475 | +228584 | +1.52% |
| 3 | State Street Corp | $116918662 | 5412901 | +835932 | +18.26% |
| 4 | Morgan Stanley | $24052175 | 1113526 | -97228 | -8.03% |
| 5 | Goldman Sachs Group Inc | $21595378 | 999786 | -168651 | -14.43% |
| 6 | Northern Trust Corp | $18150587 | 840305 | +45507 | +5.73% |
| 7 | Bank Of America Corp /De/ | $13955069 | 646068 | -354750 | -35.45% |
| 8 | Bank Of New York Mellon Corp | $11041194 | 511166 | +6704 | +1.33% |
| 9 | Invesco Ltd. | $9874318 | 414365 | +121961 | +41.71% |
| 10 | Principal Financial Group Inc | $8937605 | 413778 | +6265 | +1.54% |
| 11 | Ameriprise Financial Inc | $3457770 | 160082 | -65831 | -29.14% |
| 12 | Nomura Holdings Inc | $3039120 | 140700 | — | NEW BUY |
| 13 | Wells Fargo & Company/Mn | $2366748 | 99318 | +31002 | +45.38% |
| 14 | Citigroup Inc | $2198508 | 92258 | -4106 | -4.26% |
| 15 | Prudential Financial Inc | $1900217 | 87973 | +8515 | +10.72% |
| 16 | Barclays Plc | $1727504 | 79977 | — | NEW BUY |
| 17 | Janus Henderson Group Plc | $916406 | 42338 | — | NEW BUY |
| 18 | Raymond James Financial Inc | $815745 | 37766 | -3058 | -7.49% |
| 19 | Fifth Third Bancorp | $435694 | 20171 | +18660 | +1234.94% |
| 20 | Sei Investments Co | $222370 | 10295 | — | NEW BUY |
| 21 | Pnc Financial Services Group, Inc. | $163664 | 7577 | +316 | +4.35% |
| 22 | Royal Bank Of Canada | $102000 | 4758 | — | NEW BUY |
| 23 | Us Bancorp \De\ | $8704 | 403 | +26 | +6.90% |
| 24 | Amalgamated Financial Corp. | $171 | 5409 | — | NEW BUY |
Aggregated across tracked institutional filers. Reported quarterly on SEC Form 13-F and may lag. For research only — not investment advice.